Working… Menu

Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide (CHEMOIMMUNE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03139851
Recruitment Status : Completed
First Posted : May 4, 2017
Last Update Posted : August 27, 2020
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Centre Leon Berard

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : September 26, 2018
Actual Study Completion Date : September 18, 2019